Key Takeaway: Precision BioSciences reported its second quarter 2023 financial results, highlighting positive FDA guidance for its lead CAR T program, Azer-Cel. The company is actively pursuing CAR T partnering discussions and presented encouraging preclinical data for its ARCUS technology in treating Duchenne Muscular Dystrophy and Chronic Hepatitis B. Additionally, they plan to host an In Vivo Gene presentation.
Price reaction · baseline $16.179 (2023-08-03 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+3.8%
day 1
-1.6%
day 3
+0.1%
Market Sentiment Analysis
POSITIVE FACTORS
FDA advice clarifies future development for Azer-Cel.
Ongoing discussions for CAR T partnering indicate strong interest.
Promising preclinical data for ARCUS in treating Duchenne Muscular Dystrophy.
Plans for an In Vivo Gene presentation show proactive engagement.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– FDA Advice Provides Clarity on Future Development for Lead CAR T Program Candidate Azer-Cel; CAR T Partnering Discussions Ongoing – Presented Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy and Chronic Hepatitis B – Company plans to host In Vivo Gene
Frequently Asked Questions
What did Precision BioSciences report for Q2 2023?
The company reported its financial results and provided updates on its programs.
What is the significance of FDA advice for Azer-Cel?
The FDA advice clarifies the future development path for the CAR T program candidate.
What preclinical data was presented by Precision BioSciences?
They demonstrated the potential of ARCUS for treating Duchenne Muscular Dystrophy and Chronic Hepatitis B.
Are there any ongoing partnerships for CAR T programs?
Yes, Precision BioSciences is engaged in ongoing discussions for CAR T partnering.
What future plans does the company have?
The company plans to host a presentation on In Vivo Gene technology.